Wall Street analysts will be watching closely when Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) reports its quarterly earnings next, which is scheduled for Thu 14 Mar (In 67 Days). Looking at the latest analyst forecasts, the current earnings-per-share (EPS) consensus estimate is sitting at -$0.20 per share. In the preceding quarter, the company reportedly generated EPS of -$0.35 per share of its common stock.
Speaking of Wall Street analysts, a number of market experts at top investment banks have recently posted their updated ratings on shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Most recently, on November 6th, 2018, B. Riley FBR Upgrade a Buy rating. Before that, on September 13th, 2018, Citigroup Initiated to Buy. H.C. Wainwright Upgrade a Buy rating on August 15th, 2018, Stifel Reiterated an Buy rating on August 9th, 2018, and B. Riley FBR, Inc. Initiated a Neutral rating on March 28th, 2018.
At its current price point, combined with the fact that this company has 62.42M shares outstanding, the current market capitalization sits at 738.43M. In the last trading day, 1,306,497 shares of Dicerna Pharmaceuticals, Inc. were traded, which compares to its usual volume of about 630.35K shares per day of trading.
If we compare this company’s current price to its recent pricing activity, we can see that the price has changed by $1.70 in the past five trading days, resulting in a percentage change of +11.18% and a moving average of 11.16. In the past 20 days, its price changed by -$2.05 (which is -14.77%) and the stock’s moving average was 11.52. Looking back a full 50 days, shares of DRNA changed by -$0.50 (which is -4.06%) and demonstrated a moving average of 12.90.
Staying in the same analytical area, this company’s stock has demonstrated a 9-day Stochastic %K score of 80.28%, a 14-day Stochastic %K score of 55.22% and a 20-day Stochastic %K score of 38.31%. Using a similar metric, Dicerna Pharmaceuticals, Inc. (DRNA) shares showed a Stochastic %D of 69.87% over the past 9 days, a Stochastic %D score of 45.28% over the last 14 days, and a 20-day Stochastic %D of 32.81%. Meanwhile, this stock’s MACD Oscillator was 0.84 over the past 9 days, 0.61 over the past two weeks, and -0.02 in the last 20 days.
As recent trading data suggests, this company’s shares have been hovering close to the $11.83 level. Over the past 12 months, this stock has experienced a high price of $17.98 and a low of $8.16. Top market experts pay heightened attention to a stock as it is getting closer to a notable historic high price or low price.
Bridger Management LLC purchased more shares of this company during the last fiscal quarter, as we can observe in the latest corresponding filing from Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) with the Securities and Exchange Commission (SEC). This specific major shareholder, at the end of the quarter, held 5,530,028 shares of the company’s stock following the addition of 2,304,501 to this investor’s holdings during the three-month period. This share count represents that Bridger Management LLC now held 8.82% stake in Dicerna Pharmaceuticals, Inc. (DRNA)’s shares.
Just in the most recent trading day, Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) experienced a high price of $11.9 and low point of $10.99. At the end of the last trading session, this stock was at 11.83 per share, following a gain of $0.31, or 8.63% during the full day.